
    
      Patients remained in the treatment group to which they were originally allocated for the
      CLARINET study and continued blindly their treatment (0.2 mg/kg/day of clopidogrel or
      placebo) up to the occurrence of shunt thrombosis, next surgical procedure for correction of
      the congenital heart disease, death, or 18 months of age, whichever came first. The maximum
      treatment duration were 6 months.
    
  